Guidelines for using the QuantiFERON-TB Gold test for tuberculosis infection, United States

MMWR Recommendations and Reports 54, 49-55

Citation Report

#	Article	IF	CITATIONS
1	QuantiFERON-TB Gold: state of the art for the diagnosis of tuberculosis infection?. Expert Review of Molecular Diagnostics, 2006, 6, 663-677.	1.5	51
2	Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nature Clinical Practice Rheumatology, 2006, 2, 602-610.	3.2	242
3	Strategies for the prevention of infection after solid organ transplantation. Expert Review of Anti-Infective Therapy, 2006, 4, 837-852.	2.0	5
4	Balancing prevention and screening among international migrants with tuberculosis: Population mobility as the major epidemiological influence in low-incidence nations. Public Health, 2006, 120, 712-723.	1.4	40
5	Health risks at the Hajj. Lancet, The, 2006, 367, 1008-1015.	6.3	342
6	Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet, The, 2006, 367, 1328-1334.	6.3	468
7	An Update on the Diagnosis of Tuberculosis Infection. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 736-742.	2.5	287
8	Performance of a whole blood interferon gamma assay for detecting latent infection with Mycobacterium tuberculosis in children. Thorax, 2006, 61, 616-620.	2.7	163
10	Tuberculin Skin Test: Can it be Replaced?. Disease-a-Month, 2006, 52, 446-449.	0.4	1
11	Laboratory Diagnosis of Tuberculosis in Primary Care. Disease-a-Month, 2006, 52, 450-458.	0.4	3
12	Chemotherapy and diagnosis of tuberculosis. Respiratory Medicine, 2006, 100, 2085-2097.	1.3	41
13	Tuberculosis in Children: An Update. Advances in Pediatrics, 2006, 53, 279-322.	0.5	37
14	Infliximab in the treatment of psoriasis. Expert Review of Dermatology, 2006, 1, 515-526.	0.3	5
15	The QuantiFERON-TB Gold Test. American Journal of Nursing, 2006, 106, 33-37.	0.2	9
16	Case-Control study of Firefighters with documented positive tuberculin skin test results using Quantiferon-TB testing in comparison with Firefighters with negative tuberculin skin test results. Journal of Occupational Medicine and Toxicology, 2006, 1, 28.	0.9	1
17	Persistently elevated T cell interferon-gamma responses after treatment for latent tuberculosis infection among health care workers in India: a preliminary report. Journal of Occupational Medicine and Toxicology, 2006, 1, 7.	0.9	85
18	Guidelines for tuberculosis prophylaxis during anti-tumour necrosis factor-α treatment: Indian Rheumatology Association. APLAR Journal of Rheumatology, 2006, 9, 181-183.	0.2	17
19	New tools and emerging technologies for the diagnosis of tuberculosis: Part I. Latent tuberculosis. Expert Review of Molecular Diagnostics, 2006, 6, 413-422.	1.5	223

		CITATION R	EPORT	
#	Article		IF	CITATIONS
21	Tuberculosis and HIV: Implications in the developing world. Current HIV/AIDS Reports,	2006, 3, 139-144.	1.1	20
22	Tuberculosis vaccines: current status and future prospects. Expert Opinion on Emergin 11, 207-215.	ıg Drugs, 2006,	1.0	9
23	Serial Testing of Health Care Workers for Tuberculosis Using Interferon-Î ³ Assay. Ameri Respiratory and Critical Care Medicine, 2006, 174, 349-355.	can Journal of	2.5	255
24	Differences in the Growth of Paired Ugandan Isolates of Mycobacterium tuberculosis w Mononuclear Phagocytes Correlate with Epidemiological Evidence of Strain Virulence. Immunity, 2006, 74, 6865-6876.		1.0	27
25	Detecting a low prevalence of latent tuberculosis among health care workers in Denma M. tuberculosis specific IFN-γ whole-blood test. Scandinavian Journal of Infectious Dise 554-559.		1.5	53
26	Rates of Latent Tuberculosis in Health Care Staff in Russia. PLoS Medicine, 2007, 4, e5	5.	3.9	53
27	Usefulness of Whole-Blood Interferon-γ Assay and Interferon-γ Enzyme-Linked Immun Diagnosis of Active Pulmonary Tuberculosis. Chest, 2007, 132, 959-965.	ospot Assay in the	0.4	118
28	Comparison of an Interferon-Î ³ Release Assay with Tuberculin Skin Testing in HIV-infect American Journal of Respiratory and Critical Care Medicine, 2007, 175, 737-742.	ied Individuals.	2.5	185
29	Emerging biologics in the treatment of uveitis. Expert Review of Clinical Immunology, 2	2007, 3, 781-796.	1.3	3
30	Comparison of Two Interferon-Î ³ Assays and Tuberculin Skin Test for Tracing Tuberculo American Journal of Respiratory and Critical Care Medicine, 2007, 175, 618-627.	sis Contacts.	2.5	239
31	Recent advances in the diagnosis of childhood tuberculosis. Archives of Disease in Chil 92, 446-452.	dhood, 2007,	1.0	137
32	Enhanced Ex Vivo Stimulation of Mycobacterium tuberculosis -Specific T Cells in Huma Immunodeficiency Virus-Infected Persons via Antigen Delivery by the Bordetella pertus Cyclase Vector. Vaccine Journal, 2007, 14, 847-854.		3.2	14
33	Comparison of Mantoux and QuantiFERON TB Gold Tests for Diagnosis of Latent Tube Infection in Army Personnel. Vaccine Journal, 2007, 14, 477-480.	rculosis	3.2	37
34	Tuberculosis Control: Challenges of an Ancient and Ongoing Epidemic. Public Health R 122, 683-692.	eports, 2007,	1.3	12
35	Use in routine clinical practice of two commercial blood tests for diagnosis of infection Mycobacterium tuberculosis: a prospective study. Yearbook of Dermatology and Derm Surgery, 2007, 2007, 130.		0.0	0
36	Should Individuals Who Are Tuberculin Skin Test Negative and Positive to RD1–IFN-Î Preventive Therapy?. American Journal of Respiratory and Critical Care Medicine, 2007,	³ Assay Receive 175, 199-199.	2.5	1
37	Diagnosing Tuberculosis Infection in the 21st Century. Chest, 2007, 131, 1898-1906.		0.4	316
38	New approaches and emerging technologies in the diagnosis of childhood tuberculosis Respiratory Reviews, 2007, 8, 124-133.	. Paediatric	1.2	108

#	Article	IF	CITATIONS
40	Intraocular Tuberculosis—An Update. Survey of Ophthalmology, 2007, 52, 561-587.	1.7	593
42	The prognosis of latent tuberculosis: can disease be predicted?. Trends in Molecular Medicine, 2007, 13, 175-182.	3.5	173
43	T-cell assays for the diagnosis of latent tuberculosis infection: moving the research agenda forward. Lancet Infectious Diseases, The, 2007, 7, 428-438.	4.6	167
45	Tuberculosis and Nontuberculous Mycobacterial Infections in Older Adults. Clinics in Chest Medicine, 2007, 28, 773-781.	0.8	33
47	Tuberculosis en pacientes tratados con antagonistas del factor de necrosis tumoral alfa en un área endémica, ¿vale la pena el riesgo?. Biomedica, 2007, 27, 159.	0.3	7
48	Practical Management and Monitoring of Psoriasis Patients on Biologic Therapy: A Survey of Opinion Leaders and Practitioners. Psoriasis Forum, 2007, 13a, 4-12.	0.1	1
49	Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis and Rheumatism, 2007, 57, 756-761.	6.7	378
50	Clinical utility of an interferon-?-based assay for mycobacterial detection in papulonecrotic tuberculid. British Journal of Dermatology, 2007, 156, 169-171.	1.4	11
51	Usefulness of the QuantiFERON®test in the confirmation of latent tuberculosis in association with erythema induratum. British Journal of Dermatology, 2007, 157, 1293-1294.	1.4	28
52	Recent advances in medical dermatology. International Journal of Dermatology, 2007, 46, 1005-1010.	0.5	2
53	The Epidemiology of Tuberculosis Among Primary Refugee Arrivals in Minnesota Between 1997 and 2001. Journal of Travel Medicine, 2007, 14, 1-8.	1.4	31
54	QuantiFERON-TB gold assay for tuberculosis infection. Clinical Microbiology Newsletter, 2007, 29, 129-136.	0.4	4
55	Comparison of Quantiferon-TB Gold With Tuberculin Skin Test for Detecting Latent Tuberculosis Infection Prior to Liver Transplantation. American Journal of Transplantation, 2007, 7, 2797-2801.	2.6	110
56	Interferon Î ³ assay for detecting latent tuberculosis infection in rheumatoid arthritis patients during infliximab administration. Rheumatology International, 2007, 27, 1143-1148.	1.5	47
58	Risk factors for developing tuberculosis in remand prisons in St. Petersburg, Russia — a case-control study. European Journal of Epidemiology, 2007, 22, 121-127.	2.5	20
59	An indeterminate QuantiFERON TB-2G response for miliary tuberculosis, due to severe pancytopenia. Journal of Infection and Chemotherapy, 2007, 13, 414-417.	0.8	11
60	Evaluation of the interferon-Î ³ release assay in healthcare workers. International Archives of Occupational and Environmental Health, 2007, 81, 295-300.	1.1	56
61	Sensitivity of a Whole-Blood Interferon-Gamma Assay Among Patients with Pulmonary Tuberculosis and Variations in T-Cell Responses During Anti-Tuberculosis Treatment. Infection, 2007, 35, 98-103.	2.3	91

#	Article	IF	CITATIONS
62	Comparison of a whole blood interferon-Î ³ assay with tuberculin skin testing for the detection of tuberculosis infection in hospitalized children in rural India. Journal of Infection, 2007, 54, 267-276.	1.7	155
63	Interferon-gamma release assays in children – No better than tuberculin skin testing?. Journal of Infection, 2007, 54, 412-413.	1.7	5
64	Combined effect of Neridronate and specific antibiotic therapy in a case of tuberculous spondylodiscitis. Rheumatology International, 2008, 28, 495-498.	1.5	4
65	Performance of two commercial blood IFN-Î ³ release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-α treatment. European Journal of Clinical Microbiology and Infectious Diseases, 2008, 27, 907-913.	1.3	95
66	A contact investigation of the transmission of Mycobacterium tuberculosis from a nurse working in a newborn nursery and maternity ward. Journal of Infection and Chemotherapy, 2008, 14, 66-71.	0.8	21
67	School based screening for tuberculosis infection in Norway: comparison of positive tuberculin skin test with interferon-gamma release assay. BMC Infectious Diseases, 2008, 8, 140.	1.3	22
68	Screening for tuberculosis infection among newly arrived asylum seekers: Comparison of QuantiFERON®TB Gold with tuberculin skin test. BMC Infectious Diseases, 2008, 8, 65.	1.3	37
69	Effectiveness of the combination of a wholeâ€blood interferonâ€gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis and Rheumatism, 2008, 59, 800-806.	6.7	95
70	American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic diseaseâ€modifying antirheumatic drugs in rheumatoid arthritis. Arthritis and Rheumatism, 2008, 59, 762-784.	6.7	1,311
71	Comparison of the sensitivity and specificity of two whole blood interferon-gamma assays for M. tuberculosis infection. Journal of Infection, 2008, 56, 348-353.	1.7	92
72	The changing pattern of "smart†flow cytometry (Sâ€FC) to assist the costâ€effective diagnosis of HIV, tuberculosis, and leukemias in resourceâ€restricted conditions. Biotechnology Journal, 2008, 3, 32-42.	1.8	15
73	QuantiFERON [®] -TB Gold assay for the diagnosis of latent tuberculosis infection. Expert Review of Molecular Diagnostics, 2008, 8, 247-256.	1.5	28
74	Lack of an inverse association between tuberculosis infection and atopy: By Tâ€cellâ€based immune assay (RD1–ELISpot). Pediatric Allergy and Immunology, 2008, 19, 709-715.	1.1	10
75	Indeterminate results on the interferon-γ release assay for tuberculosis screening should not be ignored. British Journal of Dermatology, 2008, 159, 992-993.	1.4	2
76	Advances in the diagnosis of tuberculosis. Respirology, 2008, 13, S73.	1.3	5
77	Performance of QuantiFERON-TB Testing in a Tuberculosis Outbreak at a Primary School. Journal of Pediatrics, 2008, 152, 585-586.	0.9	26
78	Double-blind randomized Phase I study comparing rdESAT-6 to tuberculin as skin test reagent in the diagnosis of tuberculosis infection. Tuberculosis, 2008, 88, 249-261.	0.8	47
79	Comparison of Interferon-Gamma Release Assay <i>Versus</i> Tuberculin Skin Test for Tuberculosis Screening in Inflammatory Bowel Disease. American Journal of Gastroenterology, 2008, 103, 2799-2806.	0.2	108

#	Article	IF	CITATIONS
81	National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. Journal of the American Academy of Dermatology, 2008, 59, 209-217.	0.6	157
82	QuantiFERON TB-Gold—A New Test Strengthening Long-Suspected Tuberculous Involvement in Serpiginous-like Choroiditis. American Journal of Ophthalmology, 2008, 146, 761-766.	1.7	116
83	Late Occurrence of Pleural and Peritoneal Effusion Due to Mycobacterium tuberculosis Infection (TB) in a Patient With Posttransplantation Recurrent HCV Chronic Hepatitis: Safety of Peginterferon and Ribavirin Treatment After Recovery of TB:— A Case Report. Transplantation Proceedings, 2008, 40, 1783-1785.	0.3	7
84	Limitations of the QuantiFERON®-TB Gold test in detecting Mycobacterium tuberculosis infection in im immunocompromised patients. European Journal of Internal Medicine, 2008, 19, 137-139.	1.0	12
85	Tumor necrosis factor antagonists in the therapy of psoriasis. Clinics in Dermatology, 2008, 26, 486-502.	0.8	50
86	QuantiFERON-TB Gold and selected region of difference 1 peptide-based assays for the detection of Mycobacterium tuberculosis infection in a cohort of patients enrolled with suspected tuberculosis. Diagnostic Microbiology and Infectious Disease, 2008, 62, 395-401.	0.8	6
87	A comparative study of two different methods for the detection of latent tuberculosis in HIV-positive individuals in Chile. International Journal of Infectious Diseases, 2008, 12, 645-652.	1.5	53
88	Interferon-gamma release assays (IGRAs) in high-endemic settings: could they play a role in optimizing global TB diagnostics?. International Journal of Infectious Diseases, 2008, 12, e1-e6.	1.5	22
89	Discordant QuantiFERON-TB Gold Test Results Among US Healthcare Workers With Increased Risk of Latent Tuberculosis Infection: A Problem or Solution?. Infection Control and Hospital Epidemiology, 2008, 29, 878-886.	1.0	51
90	Cost Effectiveness of Interferon-Î ³ Release Assay for Tuberculosis Contact Screening in Japan. Molecular Diagnosis and Therapy, 2008, 12, 235-251.	1.6	28
91	Use of Whole-Blood Samples in In-House Bulk and Single-Cell Antigen-Specific Gamma Interferon Assays for Surveillance of Mycobacterium tuberculosis Infections. Vaccine Journal, 2008, 15, 327-337.	3.2	27
92	Comparison of Sensitivities of Two Commercial Gamma Interferon Release Assays for Pulmonary Tuberculosis. Journal of Clinical Microbiology, 2008, 46, 1935-1940.	1.8	113
93	Evaluation of Adapted Whole-Blood Interferon-γ Release Assays for the Diagnosis of Pleural Tuberculosis. Respiration, 2008, 76, 131-138.	1.2	66
94	Clinical Utility of the Interferon-Î ³ Release Assay for Elderly Patients With Active Tuberculosis. Chest, 2008, 134, 471-472.	0.4	6
95	Reproducibility of QuantiFERON-TB Gold In-Tube Assay. Vaccine Journal, 2008, 15, 425-432.	3.2	79
96	Enhancement of Human Antigen-Specific Memory T-Cell Responses by Interleukin-7 May Improve Accuracy in Diagnosing Tuberculosis. Vaccine Journal, 2008, 15, 1616-1622.	3.2	27
97	Enhancement of Diagnostic Efficiency by a Gamma Interferon Release Assay for Pulmonary Tuberculosis. Vaccine Journal, 2008, 15, 1028-1030.	3.2	17
98	Performance of an interferon-gamma release assay for diagnosing latent tuberculosis infection in children. Epidemiology and Infection, 2008, 136, 1179-1187.	1.0	73

#	Article	IF	CITATIONS
99	Mycobacterial Infections. , 2008, , 597-614.		0
100	Kinetoplastids: related protozoan pathogens, different diseases. Journal of Clinical Investigation, 2008, 118, 1301-1310.	3.9	460
101	Pseudoepidemics of Tuberculin Skin Test Conversions in the U.S. Army after Recent Deployments. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 1285-1289.	2.5	26
102	Predicting Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 1055-1057.	2.5	20
103	Long-term Follow-up of the QuantiFERON TB-2G Test for Active Tuberculosis Disease. Internal Medicine, 2008, 47, 1957-1961.	0.3	17
104	What is the clinical utility of interferon-Î ³ release assays for the diagnosis of TB in high-TB-burden countries?. Therapy: Open Access in Clinical Medicine, 2008, 5, 367-375.	0.2	0
105	Systematic Review: T-Cell–based Assays for the Diagnosis of Latent Tuberculosis Infection: An Update. Annals of Internal Medicine, 2008, 149, 177.	2.0	1,122
106	Improved Diagnostic Evaluation of Suspected Tuberculosis. Annals of Internal Medicine, 2008, 148, 325.	2.0	141
107	Prognostic Value of a T-Cell–Based, Interferon-γ Biomarker in Children with Tuberculosis Contact. Annals of Internal Medicine, 2008, 149, 777.	2.0	138
108	A 66-year-old Man with Hypercalcemia and Pleural Effusion. The Journal of the Japanese Society of Internal Medicine, 2008, 97, 1731-1732.	0.0	0
109	Clinical Utility of the QuantiFERON TB-2G Test for Elderly Patients With Active Tuberculosis. Chest, 2008, 133, 1196-1202.	0.4	102
110	Meta-analysis: New Tests for the Diagnosis of Latent Tuberculosis Infection: Areas of Uncertainty and Recommendations for Research. Yearbook of Pulmonary Disease, 2008, 2008, 346-347.	0.4	0
111	Respiratory infection complicating HIV infection. Current Opinion in Infectious Diseases, 2008, 21, 184-190.	1.3	25
112	Review and Clinical Perspectives for the Use of Infliximab in Ulcerative Colitis. Canadian Journal of Gastroenterology & Hepatology, 2008, 22, 261-272.	1.8	10
113	Bilateral Lymphadenopathy in a Young Woman. Baylor University Medical Center Proceedings, 2008, 21, 430-432.	0.2	3
114	T-Cell Assays for Tuberculosis Infection: Deriving Cut-Offs for Conversions Using Reproducibility Data. PLoS ONE, 2008, 3, e1850.	1.1	89
115	ESAT-6/CFP10 Skin Test Predicts Disease in M. tuberculosis-Infected Guinea Pigs. PLoS ONE, 2008, 3, e1978.	1.1	28
116	Tumour necrosis factor Î \pm inhibitors: screening for tuberculosis infection in inflammatory bowel disease. Medical Journal of Australia, 2008, 188, 168-170.	0.8	11

#	Article	IF	CITATIONS
117	The Australasian Society for Infectious Diseases guidelines for the diagnosis, management and prevention of infections in recently arrived refugees: an abridged outline. Medical Journal of Australia, 2009, 190, 421-425.	0.8	41
118	Comunicantes domiciliares jovens de pacientes com TB pulmonar na região da grande Vitória (ES): um estudo de coorte. Jornal Brasileiro De Pneumologia, 2009, 35, 359-366.	0.4	9
119	Prevalence and Risk Factors for Tuberculosis Infection among Hospital Workers in Hanoi, Viet Nam. PLoS ONE, 2009, 4, e6798.	1.1	48
120	Within-Subject Variability of Interferon-g Assay Results for Tuberculosis and Boosting Effect of Tuberculin Skin Testing: A Systematic Review. PLoS ONE, 2009, 4, e8517.	1.1	171
121	Usefulness of Interferon-Gamma Release Assays in the Diagnosis of Tuberculosis Infection in HIV-Infected Patients in Bulgaria. Biotechnology and Biotechnological Equipment, 2009, 23, 1103-1108.	0.5	15
122	Latent Tuberculosis Diagnosis in Children by Using the QuantiFERON-TB Gold In-Tube Test. Pediatrics, 2009, 123, 30-37.	1.0	152
123	Tuberculosis Epidemiology, Diagnosis and Infection Control Recommendations for Dental Settings. Journal of the American Dental Association, 2009, 140, 1092-1099.	0.7	35
124	Use of the T-SPOT. <i>TB</i> Assay to Detect Latent Tuberculosis Infection Among Rheumatic Disease Patients on Immunosuppressive Therapy. Journal of Rheumatology, 2009, 36, 546-551.	1.0	42
125	IFN-Î ³ -release assays to diagnose TB infection in the immunocompromised individual. Expert Review of Respiratory Medicine, 2009, 3, 309-327.	1.0	32
126	Comparison of Intracellular Cytokine Flow Cytometry and an Enzyme Immunoassay for Evaluation of Cellular Immune Response to Active Tuberculosis. Vaccine Journal, 2009, 16, 344-351.	3.2	27
127	Differences in Tuberculin Reactivity as Determined in a Veterans Administration Employee Health Screening Program. Vaccine Journal, 2009, 16, 541-543.	3.2	7
128	Tuberculin Skin Test Overestimates Tuberculosis Hypersensitivity in Adult Patients with Psoriasis. Dermatology, 2009, 219, 119-125.	0.9	44
129	Within-Subject Variability and Boosting of T-Cell Interferon-Î ³ Responses after Tuberculin Skin Testing. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 49-58.	2.5	169
130	The value of QuantiFERON®TB-Gold in the diagnosis of tuberculosis among dialysis patients. Nephrology Dialysis Transplantation, 2009, 24, 2252-2257.	0.4	39
131	Utility of QuantiFERON TB gold test in a south Indian patient population of ocular inflammation. Indian Journal of Ophthalmology, 2009, 57, 427.	0.5	47
132	Short-Term Reproducibility of a Commercial Interferon Gamma Release Assay. Vaccine Journal, 2009, 16, 1170-1175.	3.2	66
133	Is the QuantiFERON-TB Blood Assay a Good Replacement for the Tuberculin Skin Test in Tuberculosis Screening?. American Journal of Clinical Pathology, 2009, 132, 678-686.	0.4	24
134	Tuberculosis and Illicit Drug Use: Review and Update. Clinical Infectious Diseases, 2009, 48, 72-82.	2.9	168

#	Article	IF	CITATIONS
135	Design of immunogenic peptides from Mycobacterium tuberculosis genes expressed during macrophage infection. Tuberculosis, 2009, 89, 210-217.	0.8	11
136	IGRA tests perform similarly to TST but cause no adverse reactions: pediatric experience in Finland. BMC Research Notes, 2009, 2, 9.	0.6	28
137	Mycobacterium tuberculosis in Solid Organ Transplant Recipients. American Journal of Transplantation, 2009, 9, S57-S62.	2.6	111
138	Incidence and nature of infectious disease in patients treated with anti-TNF agents. Autoimmunity Reviews, 2009, 9, 67-81.	2.5	61
139	Latent tuberculosis infections in hard-to-reach drug using population – detection, prevention and control. Tuberculosis, 2009, 89, S41-S45.	0.8	14
140	Flow cytometric measurements of TBâ€specific T cells comparing with QuantiFERONâ€TB gold. Cytometry Part B - Clinical Cytometry, 2010, 78B, 71-80.	0.7	12
141	Comparison of performance in two diagnostic methods for tuberculosis infection. Medical Microbiology and Immunology, 2009, 198, 33-37.	2.6	24
142	Usefulness of interferon-gamma release assays for diagnosing TB infection and problems with these assays. Journal of Infection and Chemotherapy, 2009, 15, 143-155.	0.8	65
143	Clinical evaluation of QuantiFERON TB-2G test in patients with healed pulmonary tuberculosis. Journal of Infection and Chemotherapy, 2009, 15, 288-292.	0.8	6
144	Repeated tuberculin skin testing following therapy with TNF-alpha inhibitors. Clinical Rheumatology, 2009, 28, 167-172.	1.0	28
145	Quantitative T-cell interferon-gamma responses to Mycobacterium tuberculosis-specific antigens in active and latent tuberculosis. European Journal of Clinical Microbiology and Infectious Diseases, 2009, 28, 667-670.	1.3	47
146	Infectious pulmonary complications in patients treated with anti-TNF- $\hat{1}$ ± monoclonal antibodies and soluble TNF receptor. Current Infectious Disease Reports, 2009, 11, 229-236.	1.3	8
147	Poor concordance between interferon-l ³ release assays and tuberculin skin tests in diagnosis of latent tuberculosis infection among HIV-infected individuals. BMC Infectious Diseases, 2009, 9, 15.	1.3	95
148	Tuberculosis and tumour necrosis factor-α inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians. British Journal of Dermatology, 2009, 160, 8-15.	1.4	41
149	Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-γ release assay vs. tuberculin skin test. British Journal of Dermatology, 2009, 161, 797-800.	1.4	99
150	Initial results of QuantiFERON-TB Gold testing in patients with uveitis. Eye, 2009, 23, 904-909.	1.1	42
152	Role of interferon gamma release assays in tuberculosis. Respirology, 2009, 14, 156-158.	1.3	8
153	Acute effect of lowâ€flux hemodialysis process on the results of the interferonâ€gammaâ€based QuantiFERON [®] –TB Gold Inâ€Tube test in endâ€stage renal disease patients. Transplant Infectious Disease, 2009, 11, 28-32.	0.7	18

#	Article	IF	CITATIONS
154	European S3â€Guidelines on the systemic treatment of psoriasis vulgaris. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 1-70.	1.3	683
155	Transitional changes in T-cell responses to Mycobacterium tuberculosis-specific antigens during treatment. Journal of Infection, 2009, 58, 197-204.	1.7	38
156	Contact investigation in a primary school using a whole blood interferon-gamma assay. Journal of Infection, 2009, 58, 352-357.	1.7	31
157	Usefulness of the whole-blood interferon-gamma release assay for diagnosis of extrapulmonary tuberculosis. Diagnostic Microbiology and Infectious Disease, 2009, 63, 182-187.	0.8	54
158	Diagnosis of Tuberculous Uveitis: Clinical Application of an Interferon-gamma Release Assay. Ophthalmology, 2009, 116, 1391-1396.	2.5	127
159	Panorama actual en el diagnóstico de la tuberculosis cutánea. Actas Dermo-sifiliográficas, 2009, 100, 562-570.	0.2	33
160	Tuberculosis in a Solid-organ Transplant Recipient: Modern-day Implications. Journal of Heart and Lung Transplantation, 2009, 28, 191-193.	0.3	2
161	Comparison of QuantiFERON-TB Gold In-Tube Test and Tuberculin Skin Test for Identification of LatentMycobacterium tuberculosisInfection in Healthcare Staff and Association Between Positive Test Results and Known Risk Factors for Infection. Infection Control and Hospital Epidemiology, 2009, 30, 215-221.	1.0	57
162	European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. Journal of Crohn's and Colitis, 2009, 3, 47-91.	0.6	757
163	Current Panorama in the Diagnosis of Cutaneous Tuberculosis. Actas Dermo-sifiliográficas, 2009, 100, 562-570.	0.2	15
164	Novel and Improved Technologies for Tuberculosis Diagnosis: Progress and Challenges. Clinics in Chest Medicine, 2009, 30, 701-716.	0.8	118
165	Detection and diagnosis of <i>Mycobacterium tuberculosis</i> . Expert Review of Anti-Infective Therapy, 2009, 7, 1099-1108.	2.0	50
166	IFN-γ release assays in tuberculosis management in selected high-risk populations. Expert Review of Molecular Diagnostics, 2009, 9, 165-177.	1.5	15
167	Comparison of Interferon-Gamma Release Assay Versus Tuberculin Skin Test for Latent Tuberculosis Screening in Hemodialysis Patients. Biotechnology and Biotechnological Equipment, 2009, 23, 1242-1246.	0.5	7
168	QuantiFERON TB-2G test for patients with active tuberculosis stratified by age groups. Scandinavian Journal of Infectious Diseases, 2009, 41, 841-846.	1.5	23
169	Clinical utility of the QuantiFERON-TB Gold In-Tube test for the diagnosis of active pulmonary tuberculosis. Scandinavian Journal of Infectious Diseases, 2009, 41, 818-822.	1.5	33
170	Latent Infection and Tuberculosis Disease in Rheumatoid Arthritis Patients. Rheumatic Disease Clinics of North America, 2009, 35, 163-181.	0.8	16
171	Does the Implementation of an Interferon-Î ³ Release Assay in Lieu of a Tuberculin Skin Test Increase Acceptance of Preventive Therapy for Latent Tuberculosis Among Healthcare Workers?. Infection Control and Hospital Epidemiology, 2009, 30, 197-199.	1.0	18

#	Article	IF	CITATIONS
172	Reducing the Rates of Indeterminate Results of the QuantiFERON-TB Gold In-Tube Test During Routine Preemployment Screening for Latent Tuberculosis Infection Among Healthcare Personnel. Infection Control and Hospital Epidemiology, 2009, 30, 296-298.	1.0	21
173	Evaluation of the Effect of Treatment of Latent Tuberculosis Infection on QuantiFERON-TB Gold Assay Results. Infection Control and Hospital Epidemiology, 2009, 30, 392-395.	1.0	26
174	Rate of Latent Tuberculosis Infection Detected by Occupational Health Screening of Nurses New to a London Teaching Hospital. Infection Control and Hospital Epidemiology, 2009, 30, 581-584.	1.0	18
175	Screening for Tuberculosis Infection in Spanish Healthcare Workers Comparison of the QuantiFERON-TB Gold In-Tube Test with the Tuberculin Skin Test. Infection Control and Hospital Epidemiology, 2009, 30, 876-883.	1.0	33
176	Use of a T Cell Interferon- <i>γ</i> Release Assay to Evaluate Tuberculosis Risk in Newly Qualified Physicians in Singapore Healthcare Institutions. Infection Control and Hospital Epidemiology, 2009, 30, 870-875.	1.0	20
177	Annual Incidence of Latent Tuberculosis Infection among Newly Employed Nurses at a Tertiary Care University Hospital. Infection Control and Hospital Epidemiology, 2009, 30, 1218-1222.	1.0	40
178	Differentiating Intestinal Tuberculosis From Crohn's Disease: A Diagnostic Challenge. American Journal of Gastroenterology, 2009, 104, 1003-1012.	0.2	228
179	Detection of tuberculosis in HIV-infected children using an enzyme-linked immunospot assay. Aids, 2009, 23, 961-969.	1.0	35
180	New diagnostic methods for tuberculosis. Current Opinion in Infectious Diseases, 2009, 22, 174-182.	1.3	61
181	POSITIVE QUANTIFERON-TB GOLD TEST IN A PATIENT WITH MYCOBACTERIUM KANSASII INFECTION. Chest, 2009, 136, 52S.	0.4	0
182	Active Tuberculosis in Patients Undergoing Hemodialysis for End-stage Renal Disease: A 9-year Retrospective Analysis in a Single Center. Internal Medicine, 2009, 48, 2061-2067.	0.3	13
183	Comparison of an Interferon-Î ³ 947; Release Assay with Tuberculin Skin Testing in HIV-infected Individuals. Yearbook of Pulmonary Disease, 2009, 2009, 343-346.	0.4	0
184	Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: Performance of a Mycobacterium tuberculosis antigen-specific interferon Î ³ assay. Yearbook of Medicine, 2009, 2009, 75-77.	0.1	0
185	Interferon-Gamma Release Assay Improves the Diagnosis of Tuberculosis in Children. Pediatric Infectious Disease Journal, 2009, 28, 510-514.	1.1	137
186	Recent Advances in Testing for Latent TB. Chest, 2010, 138, 1456-1463.	0.4	40
187	Impact of Peripheral Lymphocyte Count on the Sensitivity of 2 IFNGAMMA. Release Assays, QFT-G and ELISPOT, in Patients with Pulmonary Tuberculosis. Internal Medicine, 2010, 49, 1849-1855.	0.3	36
188	Usefulness of Ifn-Gamma Release Assays in Clinical Management of Difficult TB Cases: Evidence from Clinical Practice. European Journal of Inflammation, 2010, 8, 43-47.	0.2	6
189	Comparison of T-Cell Interferon-Î ³ Release Assays for Mycobacterium tuberculosis-Specific Antigens in Patients with Active and Latent Tuberculosis. Lung, 2010, 188, 283-287.	1.4	30

#	Article	IF	CITATIONS
190	Comparison of tuberculin skin test and QuantiFERON-TB gold in tube test in patients with chronic inflammatory diseases living in a tuberculosis endemic population. Clinical and Experimental Medicine, 2010, 10, 173-177.	1.9	15
191	Interferon-Î ³ releasing assay versus tuberculin skin testing for latent tuberculosis infection in targeted screening programs for high risk immigrants. Infection, 2010, 38, 195-204.	2.3	25
192	Prevalence of Tuberculin Skin Test Positivity in Clinical Population in New York City. Journal of Immigrant and Minority Health, 2010, 12, 816-822.	0.8	17
193	Tuberculosis Knowledge, Attitudes, and Beliefs in Foreign-born and US-born Patients with Latent Tuberculosis Infection. Journal of Immigrant and Minority Health, 2010, 12, 859-866.	0.8	30
196	Birth cohort effect on latent tuberculosis infection prevalence, United States. BMC Infectious Diseases, 2010, 10, 206.	1.3	25
197	Serial interferon-gamma release assays during treatment of active tuberculosis in young adults. BMC Infectious Diseases, 2010, 10, 300.	1.3	42
198	Performance of QuantiFERON-TB Gold In-Tube (QFTGIT) for the diagnosis of Mycobacterium tuberculosis (Mtb) infection in Afar Pastoralists, Ethiopia. BMC Infectious Diseases, 2010, 10, 354.	1.3	26
199	Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis. BMC Pulmonary Medicine, 2010, 10, 7.	0.8	79
200	Systematic Review and Metaâ€Analysis of TST Conversion Risk in Deployed Military and Longâ€Term Civilian Travelers. Journal of Travel Medicine, 2010, 17, 233-242.	1.4	23
201	The value of an immune response to Mycobacterium tuberculosis in patients with chronic posterior uveitides revisited: utility of the new IGRAs. Eye, 2010, 24, 36-43.	1.1	33
202	Isoniazid-related bilateral choroidal effusions. Eye, 2010, 24, 1408-1409.	1.1	7
203	The immunology of tuberculosis: From bench to bedside. Respirology, 2010, 15, 433-450.	1.3	155
204	Comparison of the QuantiFERON-TB Gold In-Tube test with the tuberculin skin test for detecting latent tuberculosis infection in hemodialysis patients. Transplant Infectious Disease, 2010, 12, 98-105.	0.7	45
205	Sensitivity of the Quantiferon-Gold In-Tube Assay in Sputum Smear Positive TB Cases in Indonesia. PLoS ONE, 2010, 5, e12020.	1.1	6
206	Utilization of the QuantiFERON-TB Gold Test in a Two-Step Process with the Tuberculin Skin Test To Evaluate Health Care Workers for Latent Tuberculosis. Journal of Clinical Microbiology, 2010, 48, 2955-2956.	1.8	8
207	Diagnosis of Tuberculosis in Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1114-1122.	2.2	70
208	Management of Latent Tuberculosis Infections in Australia and New Zealand: A Review of Current Practice. Tuberculosis Research and Treatment, 2010, 2010, 1-5.	0.2	7
209	Update in Tuberculosis 2009. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 550-555.	2.5	11

ARTICLE IF CITATIONS # Kinetics of a Tuberculosis-Specific Gamma Interferon Release Assay in Military Personnel with a 210 3.2 7 Positive Tuberculin Skin Test. Vaccine Journal, 2010, 17, 937-943. Occupational Health of Animal Workers., 2010, , 343-371. Evaluation of Gamma Interferon Release Assays Using <i>Mycobacterium tuberculosis</i> Antigens for 212 Diagnosis of Latent and Active Tuberculosis in <i>Mycobacterium bovis</i> BCG-Vaccinated 3.2 44 Populations. Vaccine Journal, 2010, 17, 1985-1990. The Role of Chest CT Scanning in TB Outbreak Investigation. Chest, 2010, 137, 1057-1064. Latent Tuberculosis among Persons at Risk for Infection with HIV, Tijuana, Mexico. Emerging Infectious 214 2.0 29 Diseases, 2010, 16, 757-763. Evaluation of a modified interferon-gamma release assay for the diagnosis of latent tuberculosis infection in adult and paediatric populations that enables delayed processing. Scandinavian Journal of 1.5 Infectious Diseases, 2010, 42, 845-850. Evaluation of Quantitative IFN-Î³ Response for Risk Stratification of Active Tuberculosis Suspects. 216 2.532 American Journal of Respiratory and Critical Care Medicine, 2010, 181, 87-93. Questionable Effectiveness of the QuantiFERON-TB Gold Test (Cellestis) as a Screening Tool in 217 1.0 Healthcare Workers. Infection Control and Hospital Epidemiology, 2010, 31, 1279-1285. Management of Acute, Recurrent, and Chronic Meningitides in Adults. Neurologic Clinics, 2010, 28, 218 0.8 9 1061-1088. A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. Journal of Crohn's and Colitis, 2010, 4, 221-256. New approaches in the diagnosis and treatment of latent tuberculosis infection. Respiratory 220 1.4 67 Research, 2010, 11, 169. Pulmonary Tuberculosis Associated to Adalimumab: a Study of 3 Cases. Archivos De 0.4 Bronconeumologia, 2010, 46, 203-205. Interferon gamma release assays: principles and practice. Enfermedades Infecciosas Y MicrobiologÃa 222 0.3 131 ClÃnica, 2010, 28, 245-252. Rapidly growing neck swelling in the submandibular triangle. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2010, 110, 4-10. 1.6 Serial interferon-gamma release assays after rifampicin prophylaxis in a tuberculosis outbreak. 224 1.3 36 Respiratory Medicine, 2010, 104, 448-453. Limited usefulness of QuantiFERON-TB Gold In-Tube® for monitoring anti-tuberculosis therapy. 23 Respiratory Medicine, 2010, 104, 1551-1556. Intraocular Tuberculosis. Ocular Immunology and Inflammation, 2010, 18, 281-291. 226 1.0 48 Chronic Ulceration from Mycobacterium marinum Infection and the Diagnostic Value of T-Cell 1.6 Interferon-¹³ Release Assays. Molecular Diagnosis and Therapy, 2010, 14, 119-122.

	CITATION RE	PORT	
#	Article	IF	CITATIONS
228	Female genital tuberculosis: A review. Scandinavian Journal of Infectious Diseases, 2011, 43, 564-572.	1.5	58
229	Mycobacteria and Biological Response Modifiers: Two Sides of the Relationship. Infectious Disease Clinics of North America, 2011, 25, 865-893.	1.9	2
231	QuantiFERON-TB Gold Cut-off Value: Implications for the Management of Tuberculosis-Related Ocular Inflammation. American Journal of Ophthalmology, 2011, 152, 433-440.e1.	1.7	92
234	Laboratory Diagnosis of Tuberculosis in Resource-Poor Countries: Challenges and Opportunities. Clinical Microbiology Reviews, 2011, 24, 314-350.	5.7	387
235	TB infection and rheumatic diseases: case reports from a rheumatology center in Ahmedabad. Indian Journal of Rheumatology, 2011, 6, 40-43.	0.2	0
236	Diagnosis of osteoarticular tuberculosis. Indian Journal of Rheumatology, 2011, 6, 87-94.	0.2	9
237	A Study of Tuberculosis Infection in Workers at a University General Hospital: Associated Factors and Evolution in 20 Years. Archivos De Bronconeumologia, 2011, 47, 541-546.	0.4	2
238	Isolated Periportal Tuberculosis Causing Portal Vein Thrombosis. Journal of Ultrasound in Medicine, 2011, 30, 1599-1601.	0.8	9
239	Serial Interferon-gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection in Patients Treated with Immunosuppressive Agents. Annals of Laboratory Medicine, 2011, 31, 271-278.	1.2	31
240	Stratified Threshold Values of QuantiFERON Assay for Diagnosing Tuberculosis Infection in Immunocompromised Populations. Tuberculosis Research and Treatment, 2011, 2011, 1-9.	0.2	8
241	Tag SNP Polymorphism of CCL2 and Its Role in Clinical Tuberculosis in Han Chinese Pediatric Population. PLoS ONE, 2011, 6, e14652.	1.1	29
242	OPTIMIZING INTERPRETATION OF THE TUBERCULIN TEST USING AN INTERFERON-GAMMA RELEASE ASSAY AS A REFERENCE STANDARD. Pediatric Infectious Disease Journal, 2011, 30, 426-428.	1.1	14
244	Diagnosing latent tuberculosis infection in patients with psoriasis under antitumour necrosis factor-α treatment: every new solution breeds new doubts. British Journal of Dermatology, 2011, 164, 208-209.	1.4	4
245	Predictors of indeterminate IFN- \hat{I}^3 release assay in screening for latent TB in inflammatory bowel diseases. European Journal of Clinical Investigation, 2011, 41, 1071-1076.	1.7	35
246	Detection of proliferative responses to ESAT-6 and CFP-10 by FASCIA assay for diagnosis of Mycobacterium tuberculosis infection. Journal of Immunological Methods, 2011, 370, 55-64.	0.6	19
247	Very long standing fever in an immunocompetent host. Respiratory Medicine CME, 2011, 4, 93-95.	0.1	0
250	Comparing the performance of QuantiFERON-TB Gold and Mantoux test in detecting latent tuberculosis infection among Iranian health care workers. International Journal of Occupational Medicine and Environmental Health, 2011, 24, 359-66.	0.6	15
251	Latent Tuberculosis Infection in a Migrant Agricultural Community in Baja California, Mexico. Journal of Immigrant and Minority Health, 2011, 13, 940-947.	0.8	19

#	Article	IF	CITATIONS
252	Performance of whole-blood interferon-gamma release assay in patients admitted to the emergency department with pulmonary infiltrates. BMC Infectious Diseases, 2011, 11, 107.	1.3	13
253	Tuberculosis infection among homeless persons and caregivers in a high-tuberculosis-prevalence area in Japan: a cross-sectional study. BMC Infectious Diseases, 2011, 11, 22.	1.3	26
254	Diagnosis of latent tuberculosis infection among HIV discordant partners using interferon gamma release assays. BMC Infectious Diseases, 2011, 11, 264.	1.3	17
255	Community-based cross-sectional survey of latent tuberculosis infection in Afar pastoralists, Ethiopia, using QuantiFERON-TB Gold In-Tube and tuberculin skin test. BMC Infectious Diseases, 2011, 11, 89.	1.3	40
256	The clinical utility of tuberculin skin test and interferon-Î ³ release assay in the diagnosis of active tuberculosis among young adults: a prospective observational study. BMC Infectious Diseases, 2011, 11, 96.	1.3	22
257	Systematic review of cost and cost-effectiveness of different TB-screening strategies. BMC Health Services Research, 2011, 11, 247.	0.9	102
258	Community Engagement in Children's Environmental Health Research. Mount Sinai Journal of Medicine, 2011, 78, 85-97.	1.9	21
259	Factors impacting the results of interferon-Î ³ release assay and tuberculin skin test in routine screening for latent tuberculosis in patients with inflammatory bowel diseases. Inflammatory Bowel Diseases, 2011, 17, 84-90.	0.9	59
260	Prospective evaluation of the clinical utility of interferon-γ assay in the differential diagnosis of intestinal tuberculosis and Crohn's disease. Inflammatory Bowel Diseases, 2011, 17, 1308-1313.	0.9	34
261	Predictive factors for indeterminate result on the QuantiFERON test in an intermediate tuberculosis-burden country. Journal of Infection, 2011, 62, 347-354.	1.7	28
262	Interferon gamma release assay for differentiating tuberculosis among pneumonia cases in acute healthcare setting. Journal of Infection, 2011, 62, 440-447.	1.7	11
263	Tuberculosis: evidence review for newly arriving immigrants and refugees. Cmaj, 2011, 183, E939-E951.	0.9	85
264	Within-Subject Variability of Mycobacterium tuberculosis-Specific Gamma Interferon Responses in German Health Care Workers. Vaccine Journal, 2011, 18, 1176-1182.	3.2	65
265	Interferon-gamma release assay for diagnosing <i>Mycobacterium tuberculosis</i> infections in patients with systemic lupus erythematosus. Lupus, 2011, 20, 792-800.	0.8	19
266	Performance of a Whole-Blood Interferon-Gamma Release Assay with <i>Mycobacterium</i> RD1-Specific Antigens among HIV-Infected Persons. Clinical and Developmental Immunology, 2011, 2011, 1-6.	3.3	12
267	Update on tuberculosis: TB in the early 21st century. European Respiratory Review, 2011, 20, 71-84.	3.0	37
268	Adapted T Cell Interferon-Gamma Release Assay for the Diagnosis of Pleural Tuberculosis. Respiration, 2011, 82, 351-357.	1.2	17
269	Investigations in the diagnosis of uveitis. Expert Review of Ophthalmology, 2011, 6, 371-384.	0.3	Ο

#	Article	IF	CITATIONS
270	Suppressed Type 1, Type 2, and Type 17 Cytokine Responses in Active Tuberculosis in Children. Vaccine Journal, 2011, 18, 1856-1864.	3.2	30
271	Interferon-Gamma Release Assay Performance in Pulmonary and Extrapulmonary Tuberculosis. PLoS ONE, 2012, 7, e32652.	1.1	44
272	Psoriatic Disease and Tuberculosis Nowadays. Clinical and Developmental Immunology, 2012, 2012, 1-10.	3.3	16
273	Outbreak of Transient Conversions of the QuantiFERON-TB Gold In-Tube Test in Laboratory Health Care Worker Screenings. Vaccine Journal, 2012, 19, 954-960.	3.2	4
274	Risk Factors for Tuberculosis in Contact Investigations in Rotterdam, The Netherlands. Gastroenterology Insights, 2012, 4, e26.	0.7	3
275	Diagnostic value of ex vivo pleural fluid interferon-gamma versus adapted whole-blood quantiferon-TB gold in tube assays in tuberculous pleural effusion. Annals of Thoracic Medicine, 2012, 7, 220.	0.7	12
276	Rapid diagnosis of <i>Mycobacterium tuberculosis</i> infection in children using interferon-gamma release assays (IGRAs). Allergy and Asthma Proceedings, 2012, 33, 217-226.	1.0	12
278	Usefulness of Tuberculin Skin Test and Three Interferon-Gamma Release Assays for the Differential Diagnosis of Pulmonary Tuberculosis. Internal Medicine, 2012, 51, 1199-1205.	0.3	15
279	TUBERCULOSIS SCREENING: Prevention in the patient with immunosuppression. JAAPA: Official Journal of the American Academy of Physician Assistants, 2012, 25, 29-30.	0.1	1
280	Purified protein derivatives of tuberculin — past, present, and future. FEMS Immunology and Medical Microbiology, 2012, 66, 273-280.	2.7	80
281	Comparison of QuantiFERON-TB Gold test and tuberculin skin test for the identification of latent <i>Mycobacterium tuberculosis</i> infection in lupus patients. Lupus, 2012, 21, 491-495.	0.8	21
282	Use of ESAT-6-CFP-10 fusion protein in the bovine interferon-gamma ELISPOT assay for diagnosis of Mycobacterium bovis infection in cattle. Journal of Microbiological Methods, 2012, 90, 298-304.	0.7	4
283	From the Arm to the Test Tube: Laboratory's New Role in Tuberculosis Testing. Clinical Microbiology Newsletter, 2012, 34, 117-125.	0.4	3
284	The phenotypic distribution and functional profile of tuberculinâ€specific CD4 Tâ€cells characterizes different stages of TB infection. Cytometry Part B - Clinical Cytometry, 2012, 82B, 360-368.	0.7	17
285	Interferon-gamma release assays for the tuberculosis serial testing of health care workers: a systematic review. Journal of Occupational Medicine and Toxicology, 2012, 7, 6.	0.9	73
286	Challenges of Interferon-Î ³ Release Assay Conversions in Serial Testing of Health-care Workers in a TB Control Program. Chest, 2012, 142, 55-62.	0.4	84
287	Monthly Follow-ups of Interferon-Î ³ Release Assays Among Health-care Workers in Contact With Patients With TB. Chest, 2012, 142, 1461-1468.	0.4	48
288	The role of in vitro interferon ^{ĵ3} -release assay in differentiating intestinal tuberculosis from Crohn's disease in China. Journal of Crohn's and Colitis, 2012, 6, 317-323.	0.6	35

#	Article	IF	CITATIONS
289	Intraocular tuberculosis. Expert Review of Ophthalmology, 2012, 7, 341-349.	0.3	8
290	Tracing contacts of TB patients in Malaysia: costs and practicality. SpringerPlus, 2012, 1, 40.	1.2	8
291	Factors Associated with Indeterminate and False Negative Results of QuantiFERON-TB Gold In-Tube Test in Active Tuberculosis. Tuberculosis and Respiratory Diseases, 2012, 72, 416.	0.7	38
292	Interferon-Gamma Release Assays for Screening of Health Care Workers in Low Tuberculosis Incidence Settings: Dynamic Patterns and Interpretational Challenges. Canadian Respiratory Journal, 2012, 19, 81-83.	0.8	21
293	Application and Interpretation of an Interferon-Gamma Release Assay: Results of an Audit in a Canadian Centre. Canadian Journal of Infectious Diseases and Medical Microbiology, 2012, 23, 183-186.	0.7	0
294	Use of Interferon-Gamma Release Assays in a Health Care Worker Screening Program: Experience from a Tertiary Care Centre in the United States. Canadian Respiratory Journal, 2012, 19, 84-88.	0.8	34
295	Description of Pediatric Tuberculosis Evaluated in a Referral Center in Istanbul Turkey. Yonsei Medical Journal, 2012, 53, 1176.	0.9	10
296	Evaluation of interferon-gamma release assays for the diagnosis of tuberculosis: an updated meta-analysis. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 3127-3137.	1.3	34
297	Comparison of Quantiferon Test with Tuberculin Skin Test for the Detection of Tuberculosis Infection in Children. Inflammation, 2012, 35, 1518-1524.	1.7	10
298	Utility of QuantiFERON®-TB Gold test in diagnosis and management of suspected tubercular uveitis in India. International Ophthalmology, 2012, 32, 217-223.	0.6	47
299	Diagnostic Value of Interferon- gamma Release Assays (QuantiFERON-TB Gold® In Tube) in Childhood Tuberculosis. Indian Journal of Pediatrics, 2012, 79, 183-187.	0.3	13
300	Rv0315, a novel immunostimulatory antigen of Mycobacterium tuberculosis, activates dendritic cells and drives Th1 immune responses. Journal of Molecular Medicine, 2012, 90, 285-298.	1.7	42
301	Screening for tuberculosis and the use of a borderline zone for the interpretation of the interferon-Î ³ release assay (IGRA) in Portuguese healthcare workers. Journal of Occupational Medicine and Toxicology, 2013, 8, 1.	0.9	28
302	Implementation of an Interferon-Gamma Release Assay to Screen for Tuberculosis in Refugees and Immigrants. Journal of Immigrant and Minority Health, 2013, 15, 686-692.	0.8	6
303	IFN-γ release assay versus tuberculin skin test for monitoring TB infection in healthcare workers. Expert Review of Anti-Infective Therapy, 2013, 11, 37-48.	2.0	51
304	Clinical presentation, treatment, and outcomes in presumed intraocular tuberculosis: experience from Newcastle upon Tyne, UK. Eye, 2013, 27, 480-486.	1.1	43
305	Challenges with QuantiFERON-TB Gold Assay for Large-Scale, Routine Screening of U.S. Healthcare Workers. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 1005-1010.	2.5	89
306	Vaccines for international travel. , 2013, , 1270-1289.		5

#	Article	IF	CITATIONS
307	Point-of-care assays for tuberculosis: Role of nanotechnology/microfluidics. Biotechnology Advances, 2013, 31, 438-449.	6.0	108
308	Incidence of tuberculosis infection among healthcare workers: Risk factors and 20-year evolution. Respiratory Medicine, 2013, 107, 601-607.	1.3	25
310	Performance of Tuberculin Skin Test Compared to QFT-IT to Detect Latent TB Among High-risk Contacts in Mexico. Archives of Medical Research, 2013, 44, 242-248.	1.5	9
311	Delay in diagnosis leading to nosocomial transmission of tuberculosis at a New York City health care facility. American Journal of Infection Control, 2013, 41, 155-160.	1.1	42
312	Maternal Sepsis. Obstetrics and Gynecology Clinics of North America, 2013, 40, 69-87.	0.7	42
314	Circulating Biomarkers of Pulmonary and Extrapulmonary Tuberculosis in Children. Vaccine Journal, 2013, 20, 704-711.	3.2	61
316	Acceptability of interferon-gamma release assays among healthcare workers who receive routine employee tuberculosis testing. International Journal of Occupational and Environmental Health, 2013, 19, 319-324.	1.2	5
317	Culture confirmation of tuberculosis cases in Birmingham, UK. Scandinavian Journal of Infectious Diseases, 2013, 45, 746-751.	1.5	1
318	Blood Cells and Interferon-Gamma Levels Correlation in Latent Tuberculosis Infection. ISRN Pulmonology, 2013, 2013, 1-8.	0.3	8
319	Outbreak of Pulmonary Tuberculosis in a Chinese High School, 2009^ ^ndash;2010. Journal of Epidemiology, 2013, 23, 307-312.	1.1	15
320	An Update on Global Tuberculosis (TB). Infectious Diseases: Research and Treatment, 2013, 6, IDRT.S11263.	0.7	11
321	Predictive value of interferon-gamma release assays for postpartum active tuberculosis in HIV-1-infected women. International Journal of Tuberculosis and Lung Disease, 2013, 17, 1552-1557.	0.6	8
322	Hypoalbuminemia and Lymphocytopenia are Predictive Risk Factors for In-hospital Mortality in Patients with Tuberculosis. Internal Medicine, 2013, 52, 439-444.	0.3	31
323	Prevalence and Incidence of Latent Tuberculosis Infection in Georgian Healthcare Workers. PLoS ONE, 2013, 8, e58202.	1.1	45
324	Plasma Heme Oxygenase-1 Levels Distinguish Latent or Successfully Treated Human Tuberculosis from Active Disease. PLoS ONE, 2013, 8, e62618.	1.1	58
325	Indeterminate T-SPOT. <i>TB</i> Test Results in Patients with Suspected Extrapulmonary Tuberculosis in Routine Clinical Practice. Infection and Chemotherapy, 2013, 45, 44.	1.0	21
326	Serial QuantiFERON-TB Gold In-Tube assay and tuberculin skin test to diagnose latent tuberculosis in household Mexican contacts: conversion and reversion rates and associated factors using conventional and borderline zone definitions. Memorias Do Instituto Oswaldo Cruz, 2014, 109, 863-870.	0.8	6
327	Performance of QuantiFERON-TB Gold In-Tube test and Tuberculin Skin Test for diagnosis of latent tuberculosis infection in BCG vaccinated health care workers. Medical Science Monitor, 2014, 20, 521-529.	0.5	12

#	Article	IF	CITATIONS
328	The Usefulness of Interferon-gamma Release Assay for Diagnosis of Tuberculosis-related Uveitis in Korea. Korean Journal of Ophthalmology: KJO, 2014, 28, 226.	0.5	16
329	Helminth Infection Increases the Probability of Indeterminate QuantiFERON Gold in Tube Results in Pregnant Women. BioMed Research International, 2014, 2014, 1-5.	0.9	16
330	Infections and arthritis. Best Practice and Research in Clinical Rheumatology, 2014, 28, 935-959.	1.4	74
331	Application of the QuantiFERON®-TB Gold test in Erythema Induratum. Journal of Dermatological Treatment, 2014, 25, 260-263.	1.1	5
332	Differential diagnosis of intestinal tuberculosis from Crohn′s disease and primary intestinal lymphoma in China. Saudi Journal of Gastroenterology, 2014, 20, 241.	0.5	13
333	Flight related tuberculosis contact investigations in the United States: Comparative risk and economic analysis of alternate protocols. Travel Medicine and Infectious Disease, 2014, 12, 54-62.	1.5	10
334	Interferon-gamma release assays for tuberculosis: current and future applications. Expert Review of Respiratory Medicine, 2014, 8, 67-78.	1.0	36
335	Costâ€effectiveness of Using Quantiferon Gold (<scp>QFT</scp> â€G) [®] versus Tuberculin Skin Test (<scp>TST</scp>) among U.S. and Foreign Born Populations at a Public Health Department Clinic with a Low Prevalence of Tuberculosis. Public Health Nursing, 2014, 31, 144-152.	0.7	14
336	Differential Diagnosis of Crohn's Disease Versus Ileal Tuberculosis. Current Gastroenterology Reports, 2014, 16, 418.	1.1	24
337	The utility of routine tuberculosis screening in county hospital patients with uveitis. British Journal of Ophthalmology, 2014, 98, 1091-1095.	2.1	28
338	Screening for latent tuberculosis infection in psoriasis and psoriatic arthritis patients in a tuberculosisâ€endemic country: a comparison of the Quanti <scp>FERON</scp> [®] â€ <scp>TB</scp> Gold Inâ€Tube test and tuberculin skin test. International Journal of Dermatology, 2014, 53, 1286-1292.	0.5	20
339	Systematic review with metaâ€analysis: Accuracy of interferonâ€gamma releasing assay and antiâ€ <i><scp>S</scp>accharomyces cerevisiae</i> antibody in differentiating intestinal tuberculosis from <scp>C</scp> rohn's disease in <scp>A</scp> sians. Journal of Gastroenterology and Hepatology (Australia). 2014. 29. 1664-1670.	1.4	66
340	Comparative study of concordance and costs between tuberculin skin test and QuantiFERON®-TB Gold In-Tube in the diagnosis of latent tuberculosis infection among contacts of patients with pulmonary tuberculosis. Medicina ClÂnica (English Edition), 2015, 145, 427-432.	0.1	0
341	Reversible Hypopituitarism with Pituitary Tuberculoma. Internal Medicine, 2015, 54, 1247-1251.	0.3	14
342	Quantiferon <scp>TB</scp> â€ <scp>G</scp> old conversion can predict active tuberculosis development in elderly nursing home residents. Geriatrics and Gerontology International, 2015, 15, 1179-1184.	0.7	8
343	Diagnosis of latent Mycobacterium tuberculosis infection: tuberculin test versus interferon-gamma release. Revista Da Sociedade Brasileira De Medicina Tropical, 2015, 48, 724-730.	0.4	4
344	The Prevalence Rate of Tuberculin Skin Test Positive by Contacts Group to Predict the Development of Active Tuberculosis After School Outbreaks. Tuberculosis and Respiratory Diseases, 2015, 78, 349.	0.7	2
345	Ocular tuberculosis: current perspectives. Clinical Ophthalmology, 2015, 9, 2223.	0.9	101

	CITATION	CITATION REPORT	
#	Article	IF	Citations
346	Gamma Interferon Assays Used in the Diagnosis of Tuberculosis. Vaccine Journal, 2015, 22, 845-849.	3.2	10
347	Tuberculin skin test and Quantiferon test agreement and influencing factors in tuberculosis screening of healthcare workers: a systematic review and meta-analysis. Journal of Occupational Medicine and Toxicology, 2015, 10, 2.	0.9	25
348	Safety issues and concerns of new immunomodulators in rheumatology. Expert Opinion on Drug Safety, 2015, 14, 389-399.	1.0	34
350	The impact of immunosuppressive therapy on QuantiFERON and tuberculin skin test for screening of latent tuberculosis in patients with inflammatory bowel disease scheduled for anti-TNF therapy. Scandinavian Journal of Gastroenterology, 2015, 50, 1451-1455.	0.6	14
351	Relation between Recurrence of Tuberculosis and Transitional Changes in IFN-Î ³ Release Assays. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 480-483.	2.5	4
352	The assessment of cytokines in Quantiferon supernatants for the diagnosis of latent TB infection in a tribal population of Melghat, India. Journal of Infection and Public Health, 2015, 8, 329-340.	1.9	11
354	A Case of Reactive Cervical Lymphadenopathy with Fat Necrosis Impinging on Adjacent Vascular Structures. Case Reports in Otolaryngology, 2016, 2016, 1-4.	0.1	1
355	Poor agreement between diagnostic tests for latent tuberculosis infection among HIVâ€infected persons in Hong Kong. Respirology, 2016, 21, 1322-1329.	1.3	8
356	Lysine Scanning of Arg ₁₀ –Teixobactin: Deciphering the Role of Hydrophobic and Hydrophilic Residues. ACS Omega, 2016, 1, 1262-1265.	1.6	51
357	Association Between Staff Experience and Effective Tuberculosis Contact Tracing in North Carolina, 2008-2009. North Carolina Medical Journal, 2016, 77, 37-44.	0.1	1
358	Multidrug-resistant tuberculosis outbreak in an Italian prison: tolerance of pyrazinamide plus levofloxacin prophylaxis and serial interferon gamma release assays. New Microbes and New Infections, 2016, 12, 45-51.	0.8	6
359	Risk management for prescribing biological therapies. Revista Colombiana De ReumatologÃa (English) Tj ETQ	q1 1 0,78431 0.1	14 rgBT /Ovei
360	Typical and Atypical Mycobacterium Infections After Hematopoietic Stem Cell or Solid Organ Transplantation. , 2016, , 381-395.		1
361	Mycobacterium tuberculosis infections in cynomolgus monkey transplant recipients and institution of a screening program for the prevention and control of tuberculosis. BMC Veterinary Research, 2016, 12, 289.	0.7	4
362	Interferon-gamma release assays in patients with Mycobacterium kansasii pulmonary infection: A retrospective survey. Journal of Infection, 2016, 72, 706-712.	1.7	14
363	Performance of interferon-Î ³ release assays in the diagnosis of confirmed active tuberculosis in immunocompetent children: a new systematic review and meta-analysis. BMC Infectious Diseases, 2016, 16, 131.	1.3	39
364	Tuberculin and QuantiFERON-TB-Gold tests for latent tuberculosis: a meta-analysis. Occupational Medicine, 2016, 66, 437-445.	0.8	16
365	Prevalence of latent tuberculosis infection in persons with and without human immunodeficiency virus infection using two interferon-gamma release assays and tuberculin skin test in a low human immunodeficiency virus prevalence, intermediate tuberculosis-burden country. Journal of Microbiology, Immunology and Infection, 2016, 49, 729-736.	1.5	14

#	Article	IF	CITATIONS
366	Concordance between the tuberculin skin test and interferon gamma release assay (IGRA) for diagnosing latent tuberculosis infection in patients with systemic lupus erythematosus and patient characteristics associated with an indeterminate IGRA. Lupus, 2016, 25, 1341-1348.	0.8	14
368	Utility of QuantiFERON-TB Gold In-Tube Test in the Diagnosis of Latent TB in HIV-Positive Patients in a Medium-TB Burden Country. Journal of the International Association of Providers of AIDS Care, 2016, 15, 101-106.	0.6	3
369	Microbiologic Diagnosis of Lung Infection. , 2016, , 278-298.e7.		1
370	Tuberculosis en lactantes menores de 3 meses. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2017, 35, 243-245.	0.3	6
371	Diagnostic utility of QuantiFERON–TB Gold In-Tube test in pediatric tuberculosis disease in Taiwanese children. Journal of Microbiology, Immunology and Infection, 2017, 50, 349-354.	1.5	11
372	Diagnostic potential of interferonâ€gamma release assay to detect latent tuberculosis infection in kidney transplant recipients. Transplant Infectious Disease, 2017, 19, e12675.	0.7	20
373	Tuberculin skin test and interferon-gamma release assay use among privately insured persons in the United States. International Journal of Tuberculosis and Lung Disease, 2017, 21, 684-689.	0.6	4
374	Serial Tuberculosis Screening in Inflammatory Bowel Disease Patients Receiving Anti-TNFα Therapy. Journal of Crohn's and Colitis, 2017, 11, 1223-1229.	0.6	18
375	Tuberculosis in infants less than 3 months of age. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2017, 35, 243-245.	0.2	1
376	Cutaneous Tuberculosis. , 2017, , 11-125.		1
377	Detecting New <i>Mycobacterium tuberculosis</i> Infection. Time for a More Nuanced Interpretation of QuantiFERON Conversions. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 546-547.	2.5	11
378	Testing of tuberculosis infection among Chinese adolescents born after terminating the Bacillus Calmette–Guérin booster vaccination: subgroup analysis of a population-based cross-sectional study. Frontiers of Medicine, 2017, 11, 528-535.	1.5	12
379	Development and Validation of a Novel Prediction Model for Differential Diagnosis Between Crohn's Disease and Intestinal Tuberculosis. Inflammatory Bowel Diseases, 2017, 23, 1614-1623.	0.9	37
380	Assessment of the QuantiFERON-TB Gold In-Tube test for the detection of Mycobacterium tuberculosis infection in United States Navy recruits. PLoS ONE, 2017, 12, e0177752.	1.1	11
381	The Clinical Manifestations and Differential Diagnosis of Tuberculosis Serpiginous-like Choroiditis and Serpiginous Choroiditis. Journal of Korean Ophthalmological Society, 2017, 58, 50.	0.0	0
382	Effect of Low Charge and High Hydrophobicity on Antimicrobial Activity of the Quinazolinone-Peptide Conjugates. Russian Journal of Bioorganic Chemistry, 2018, 44, 158-164.	0.3	27
383	Synthesis and antibacterial studies of teixobactin analogues with non-isostere substitution of enduracididine. Bioorganic and Medicinal Chemistry, 2018, 26, 1062-1068.	1.4	29
384	Practical Guidance for Clinical Microbiology Laboratories: Mycobacteria. Clinical Microbiology Reviews, 2018, 31, .	5.7	175

#	Article	IF	CITATIONS
385	Evaluation of interferon-gamma release assays in extrasanguinous body fluids for diagnosing tuberculosis: A systematic review and meta-analysis. Life Sciences, 2018, 197, 140-146.	2.0	7
386	Indeterminate QuantiFERON-TB Gold Increases Likelihood of Inflammatory Bowel Disease Treatment Delay and Hospitalization. Inflammatory Bowel Diseases, 2018, 24, 217-226.	0.9	9
387	Tuberculin Skin Test Conversions and Occupational Exposure Risk in US Healthcare Workers. Clinical Infectious Diseases, 2018, 66, 706-711.	2.9	17
388	Teixobactin as a scaffold for unlimited new antimicrobial peptides: SAR study. Bioorganic and Medicinal Chemistry, 2018, 26, 2788-2796.	1.4	40
389	Recombinant O-mannosylated protein production (PstS-1) from Mycobacterium tuberculosis in Pichia pastoris (Komagataella phaffii) as a tool to study tuberculosis infection. Microbial Cell Factories, 2019, 18, 11.	1.9	9
390	QuantiFERON-TB Gold Versus Tuberculin Screening and Care Retention Among Persons Experiencing Homelessness: Georgia, 2015–2017. American Journal of Public Health, 2019, 109, 1028-1033.	1.5	3
391	Screening for latent tuberculosis infection prior to biologic therapy in patients with chronic immune-mediated inflammatory diseases (IMID): Interferon-gamma release assay (IGRA) versus tuberculin skin test (TST). Egyptian Rheumatologist, 2019, 41, 225-230.	0.5	6
392	A tuberculosis school outbreak in China, 2018: reaching an often overlooked adolescent population. Epidemiology and Infection, 2019, 147, e303.	1.0	9
393	Screening of healthcare workers for latent tuberculosis infection in the low tuberculosis burden country: QuantiFERON-TB gold in tube test or tuberculin skin test?. Archives of Environmental and Occupational Health, 2019, 74, 109-114.	0.7	8
394	Interpretation of serial interferon-gamma test results to measure new tuberculosis infection among household contacts in Zambia and South Africa. BMC Infectious Diseases, 2020, 20, 760.	1.3	2
395	Whole-genome sequencing and epidemiological analysis of a tuberculosis outbreak in a high school of southern China. Infection, Genetics and Evolution, 2020, 83, 104343.	1.0	6
396	Performance of Interferon-Gamma Release Assays in the Diagnosis of Nontuberculous Mycobacterial Diseases—A Retrospective Survey From 2011 to 2019. Frontiers in Cellular and Infection Microbiology, 2020, 10, 571230.	1.8	11
397	Heme oxygenase-1 and neopterin plasma/serum levels and their role in diagnosing active and latent TB among HIV/TB co-infected patients: a cross sectional study. BMC Infectious Diseases, 2021, 21, 711.	1.3	1
398	Interferon gamma release assays for detection of latent Mycobacterium tuberculosis in older Hispanic people. International Journal of Infectious Diseases, 2021, 111, 85-91.	1.5	12
400	Screening for Public Purpose: Promoting an Evidence-based Approach to Screening of Inmates to Improve Public Health. , 2007, , 249-264.		2
401	IL-7 Addition Increases Spot Size and Number as Measured by T-SPOT.TB ®. Methods in Molecular Biology, 2012, 792, 229-241.	0.4	7
402	Infection Prevention and Control Issues After Solid Organ Transplantation. , 2016, , 843-867.		3
403	Tuberculosis and other mycobacterial infections. , 2010, , 309-327.		20

#	Article	IF	CITATIONS
404	Mycobacterium tuberculosis. , 2010, , 3129-3163.		23
405	Infections in Recipients of Hematopoietic Cell Transplantation. , 2010, , 3821-3837.		2
406	Tuberculosis vaccines. , 2008, , 857-885.		2
408	Tuberculosis in Travelers and Immigrants. , 2008, , 391-406.		1
409	Intestinal tuberculosis and Crohn's disease: the dilemma of similarities and misdiagnosis. BMJ Case Reports, 2009, 2009, bcr0420091729-bcr0420091729.	0.2	5
410	Management of Infants and Children who are Contacts of Contagious Tuberculous Patients = ÙØ¹Ø§Ù"جة Sultan Qaboos University Medical Journal, 2013, 13, 477-485.	الر	ضع Ù^ اÙ
411	Loss of Receptor on Tuberculin-Reactive T-Cells Marks Active Pulmonary Tuberculosis. PLoS ONE, 2007, 2, e735.	1.1	96
412	Heparin-Binding-Hemagglutinin-Induced IFN-γ Release as a Diagnostic Tool for Latent Tuberculosis. PLoS ONE, 2007, 2, e926.	1.1	114
413	A Three-Way Comparison of Tuberculin Skin Testing, QuantiFERON-TB Gold and T-SPOT.TB in Children. PLoS ONE, 2008, 3, e2624.	1.1	168
414	Evaluation of the Prognostic Value of IFN-γ Release Assay and Tuberculin Skin Test in Household Contacts of Infectious Tuberculosis Cases in Senegal. PLoS ONE, 2010, 5, e10508.	1.1	51
415	High Annual Risk of Tuberculosis Infection among Nursing Students in South India: A Cohort Study. PLoS ONE, 2011, 6, e26199.	1.1	32
416	Diagnostic Performance of Interferon-Gamma Releasing Assay in HIV-Infected Patients in China. PLoS ONE, 2013, 8, e70957.	1.1	8
417	Tuberculin Skin Test Distribution following a Change in BCG Vaccination Policy. PLoS ONE, 2014, 9, e86419.	1.1	9
418	Discordance of Tuberculin Skin Test and Interferon Gamma Release Assay in Recently Exposed Household Contacts of Pulmonary TB Cases in Brazil. PLoS ONE, 2014, 9, e96564.	1.1	26
419	Comparison of the Tuberculin Skin Test and Interferon Gamma Release Assay for the Screening of Tuberculosis in Adolescents in Close Contact with Tuberculosis TB Patients. PLoS ONE, 2014, 9, e100267.	1.1	14
420	Enduring Challenge of Latent Tuberculosis in Older Nursing Home Residents: A Brief Review. Journal of Clinical Medicine Research, 2019, 11, 385-390.	0.6	5
421	Bacteriology of Childhood Tuberculosis in Ibadan, Nigeria: A Five-year review. Tropical Medicine and Health, 2008, 36, 127-130.	1.0	4
422	Serial testing with an interferon-Î ³ release assay in German healthcare workers. GMS Krankenhaushygiene InterdisziplinĤ 2010, 5, .	0.3	23

#	Article	IF	CITATIONS
423	Predictors of low prevalence of latent tuberculosis infection among Egyptian health care workers at intensive care and bronchoscopy units. GMS Hygiene and Infection Control, 2016, 11, Doc22.	0.2	3
424	Poor agreement between QuantiFERON-TB Gold test and tuberculin skin test results for the diagnosis of latent tuberculosis infection in rheumatoid arthritis patients and healthy controls. Korean Journal of Internal Medicine, 2014, 29, 76.	0.7	11
425	Qualitative and quantitative results of interferon- $\hat{1}^3$ release assays for monitoring the response to anti-tuberculosis treatment. Korean Journal of Internal Medicine, 2017, 32, 302-308.	0.7	10
426	Comparison of QuantiFERON-TB gold in tube test versus tuberculin skin test for screening of latent tuberculosis infection in Saudi Arabia: A population-based study. Annals of Thoracic Medicine, 2016, 11, 197.	0.7	3
427	Diagnosis of latent tuberculosis: Can we do better?. Annals of Thoracic Medicine, 2009, 4, 5.	0.7	58
428	Performance of QuantiFERON-TB Gold test compared to tuberculin skin test in detecting latent tuberculosis infection in HIV- positive individuals in Iran. Annals of Thoracic Medicine, 2010, 5, 43.	0.7	22
429	Tubercular subretinal abscess in a pediatric intermediate uveitis patient on methotrexate. Indian Journal of Ophthalmology, 2020, 68, 2043.	0.5	3
430	Comparison of the tuberculin skin test and the QuantiFERON-TB Gold test in detecting latent tuberculosis in health care workers in Iran. Epidemiology and Health, 2016, 38, e2016032.	0.8	9
431	Do the tuberculin skin test and the QuantiFERON-TB Gold in-tube test agree in detecting latent tuberculosis among high-risk contacts? A systematic review and meta-analysis. Epidemiology and Health, 2015, 37, e2015043.	0.8	11
432	Intraocular Tuberculosis. Journal of Postgraduate Medicine Education and Research, 2013, 47, 193-201.	0.1	1
433	Differences in Clinical Manifestations according to the Positivity of Interferon-Î ³ Assay in Patients with Intestinal Tuberculosis. Gut and Liver, 2016, 10, 649-652.	1.4	6
434	Primary cavitary tuberculosis in an infant. Turk Pediatri Arsivi, 2018, 53, 189-192.	0.9	1
435	Prevention and Treatment of Infection in Kidney Transplant Recipients. , 2008, , 1034-1046.		1
436	Comparison of a whole blood Interferon-γ assay and A tuberculin skin test for detecting latent tuberculosis infection in children. Korean Journal of Pediatrics, 2008, 51, 971.	1.9	1
437	Separating Latent and Acute Disease in the Diagnosis of Tuberculosis. , 2008, , 91-99.		0
438	Treatment of latent tuberculous infection in children and adolescent. Korean Journal of Pediatrics, 2009, 52, 519.	1.9	1
441	Infections in the Immunocompromised Host. , 2010, , 361-375.		1
443	Mycobacterium tuberculous Infection. , 2011, , 455-461.		0

#	Article	IF	CITATIONS
445	The Genomics of Leprosy. Advances in Microbial Ecology, 2012, , 39-49.	0.1	0
446	Comparison of the Tuberculin Skin Test and the Interferon-Î ³ Release Assay for the Diagnosis of Cervical Tuberculous Lymphadenitis. Korean Journal of Otorhinolaryngology-Head and Neck Surgery, 2013, 56, 354.	0.0	3
447	Infections in Recipients of Hematopoietic Stem Cell Transplants. , 2015, , 3425-3439.e5.		2
450	Donor-Derived Infections: Incidence, Prevention, and Management. , 2016, , 113-127.		0
451	Tuberculin Skin Test and Interferon-γ Release Assays in the Diagnosis of Ocular Tuberculosis. Essentials in Ophthalmology, 2017, , 35-49.	0.0	0
452	Interleukin-6, Interleukin-17 and Transforming Growth Factor-Beta are Overexpressed in Newly Diagnosed Tuberculosis Patients; Potent Biomarkers of Mycobacterial Infection. Archives of Clinical Infectious Diseases, 2019, 14, .	0.1	3
453	Immunological tests and their interpretation in uveitis. Indian Journal of Ophthalmology, 2020, 68, 1737.	0.5	10
454	Nanomedicines in Tuberculosis: Diagnosis, Therapy and Nanodrug Delivery. Engineering Materials, 2020, , 357-404.	0.3	0
455	Should we continue to perform medical thoracoscopy in pleural tuberculosis?. Minerva Respiratory Medicine, 2020, 58, .	0.1	0
456	GEBELİKTE TÜBERKÜLOZ. Bozok Tıp Dergisi, 0, , .	0.0	0
458	Prevalence and risk factors for latent tuberculosis infection among health care workers in Georgia. International Journal of Tuberculosis and Lung Disease, 2008, 12, 513-9.	0.6	50
459	High prevalence of latent tuberculosis infection among injection drug users in Tijuana, Mexico. International Journal of Tuberculosis and Lung Disease, 2009, 13, 626-32.	0.6	29
461	Improving the estimation of tuberculosis infection prevalence using T-cell-based assay and mixture models. International Journal of Tuberculosis and Lung Disease, 2008, 12, 895-902.	0.6	29
463	T-cell assay conversions and reversions among household contacts of tuberculosis patients in rural India. International Journal of Tuberculosis and Lung Disease, 2009, 13, 84-92.	0.6	104
464	Mycobacterium tuberculosis infection in a closed colony of rhesus macaques (Macaca mulatta). Journal of the American Association for Laboratory Animal Science, 2011, 50, 105-8.	0.6	11
467	Differential diagnosis between Crohn's disease and intestinal tuberculosis using integrated parameters including clinical manifestations, T-SPOT, endoscopy and CT enterography. International Journal of Clinical and Experimental Medicine, 2015, 8, 17578-89.	1.3	12
468	Current preventive policies and practices against Vaccine-Preventable Diseases and tuberculosis targeted for workers from hospitals of the Sardinia Region, Italy. Journal of Preventive Medicine and Hygiene, 2016, 57, E69-74.	0.9	7
469	A Case of Extrapulmonary Tuberculosis Two-Ways. Kansas Journal of Medicine, 2019, 12, 20-21.	0.1	0

#	Article	IF	CITATIONS
470	The diagnostic challenge of identifying miliary tuberculosis with chest radiography. Oxford Medical Case Reports, 2022, 2022, omac015.	0.2	0
471	Tuberculosis Risk in Health Care Workers. The Indian Journal of Chest Diseases & Allied Sciences, 2022, 55, 149-154.	0.1	9